IONS
What one share of Ionis Pharmaceuticals holds
Pharmaceutical Preparations
For three decades, we have invented medicines that bring better futures to people with serious diseases. As a pioneer in RNA-targeted medicines with a deep understanding of disease biology and an industry-leading drug discovery technology, we are driven to deliver innovative, life-changing advances for patients.
Ionis Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $5.36 |
|---|---|
| Profit | −$3.46 |
| Capex (buildings and equipment) | $0.39 |
| Free cash flow | −$3.44 |
| Cash and investments | $2.11 |
| Debt | $10.63 |
| Book value | $2.65 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2008 | $1.13 | −$0.19 | $0.14 | $2.10 | — | $1.56 |
| 2009 | $1.24 | $1.58 | $0.14 | −$1.24 | — | $2.95 |
| 2010 | $1.09 | −$0.62 | $0.13 | −$0.77 | — | $2.46 |
| 2011 | $0.99 | −$0.85 | $0.10 | −$1.25 | — | $1.71 |
| 2012 | $1.01 | −$0.65 | $0.01 | $0.00 | — | $1.80 |
| 2013 | $1.33 | −$0.55 | $0.01 | $0.56 | — | $3.25 |
| 2014 | $1.82 | −$0.33 | $0.06 | −$0.01 | — | $2.18 |
| 2015 | $2.37 | −$0.74 | $0.06 | $0.11 | — | $1.67 |
| 2016 | $2.87 | −$0.50 | $0.06 | −$0.99 | — | $0.82 |
| 2017 | $4.03 | $0.15 | $0.28 | $1.11 | — | $2.25 |
| 2018 | $4.47 | $2.07 | $0.10 | $4.40 | — | $7.60 |
| 2019 | $7.33 | $1.90 | $0.20 | $2.05 | — | $10.48 |
| 2020 | $5.22 | −$3.18 | $0.25 | $0.01 | — | $5.30 |
| 2021 | $5.75 | −$0.20 | $0.08 | $0.13 | — | $5.47 |
| 2022 | $4.14 | −$1.90 | $0.11 | −$2.05 | — | $4.03 |
| 2023 | $5.50 | −$2.56 | $0.17 | −$2.31 | — | $2.68 |
| 2024 | $4.72 | −$3.04 | $0.30 | −$3.65 | — | $3.73 |
| 2025 | $5.90 | −$2.38 | $0.32 | −$2.00 | — | $2.99 |